Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4201
Tenaris
TS
$28.9B
| $191K | ﹤0.01% |
6,020
+6,000
| +30,000% | +$178K |
|
4202
Lineage Cell Therapeutics
LCTX
$272M
| $191K | ﹤0.01% |
211,300
+159,924
| +311% | +$148K |
|
4203
Stratus Properties
STRS
$157M
| $191K | ﹤0.01% |
7,335
+5,411
| +281% | +$141K |
|
4204
Motley Fool 100 Index ETF
TMFC
$2.05B
| $191K | ﹤0.01% |
3,387
+1,781
| +111% | +$96.5K |
|
|
XDJL
4205
DELISTED
Innovator US Equity Accelerated ETF July
XDJL
| $190K | ﹤0.01% |
+5,613
| New | +$184K |
|
4206
Citizens
CIA
$240M
| $190K | ﹤0.01% |
52,379
+10,267
| +24% | +$30K |
|
4207
Shattuck Labs
STTK
$682M
| $190K | ﹤0.01% |
54,311
+40,717
| +300% | +$152K |
|
|
GBIO
4208
DELISTED
Generation Bio
GBIO
| $189K | ﹤0.01% |
7,643
+4,764
| +165% | +$126K |
|
|
ORLA
4209
Orla Mining
ORLA
$3.54B
| $189K | ﹤0.01% |
47,177
+21,877
| +86% | +$86.7K |
|
4210
PUT
Astera Labs
ALAB
$54.3B
| $189K | ﹤0.01% |
+3,600
| New | +$169K |
|
4211
PepGen
PEPG
$122M
| $188K | ﹤0.01% |
21,971
+16,723
| +319% | +$198K |
|
4212
Innovator US Equity Accelerated Plus ETF April
XTAP
$22.8M
| $187K | ﹤0.01% |
+5,563
| New | +$182K |
|
4213
Cartesian Therapeutics
RNAC
$224M
| $187K | ﹤0.01% |
11,611
+7,849
| +209% | +$123K |
|
|
OBE
4214
Obsidian Energy
OBE
$713M
| $187K | ﹤0.01% |
33,690
+15,664
| +87% | +$105K |
|
4215
X4 Pharmaceuticals
XFOR
$375M
| $186K | ﹤0.01% |
9,256
+6,129
| +196% | +$128K |
|
4216
Cardlytics
CDLX
$21.8M
| $186K | ﹤0.01% |
5,803
+4,012
| +224% | +$223K |
|
4217
Twin Disc
TWIN
$330M
| $186K | ﹤0.01% |
14,863
+10,959
| +281% | +$141K |
|
4218
Escalade
ESCA
$274M
| $186K | ﹤0.01% |
13,185
+9,432
| +251% | +$130K |
|
|
SCPH
4219
DELISTED
scPharmaceuticals
SCPH
| $185K | ﹤0.01% |
40,644
+30,902
| +317% | +$149K |
|
4220
Riskified
RSKD
$696M
| $185K | ﹤0.01% |
39,174
+20,213
| +107% | +$110K |
|
4221
Northern Technologies International Corp
NTIC
$77.6M
| $183K | ﹤0.01% |
14,864
+6,533
| +78% | +$86.2K |
|
4222
Cadiz
CDZI
$257M
| $182K | ﹤0.01% |
60,217
+45,728
| +316% | +$149K |
|
4223
Clarus
CLAR
$123M
| $182K | ﹤0.01% |
40,478
+29,340
| +263% | +$148K |
|
|
OPI
4224
DELISTED
Office Properties Income Trust
OPI
| $181K | ﹤0.01% |
83,246
+48,807
| +142% | +$111K |
|
4225
Scilex Holding
SCLX
$48M
| $181K | ﹤0.01% |
5,585
| – | – |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.